Division of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, CA, United States.
Department of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA, United States.
Front Immunol. 2022 Jul 7;13:893177. doi: 10.3389/fimmu.2022.893177. eCollection 2022.
Clinical successes using current T-cell based immunotherapies have been limited in soft tissue sarcomas (STS), while pre-clinical studies have shown evidence of natural killer (NK) cell activity. Since tumor immune infiltration, especially tumor-infiltrating lymphocytes, is associated with improved survival in most solid tumors, we sought to evaluate the gene expression profile of tumor and blood NK and T cells, as well as tumor cells, with the goal of identifying potential novel immune targets in STS.
Using fluorescence-activated cell sorting, we isolated blood and tumor-infiltrating CD3CD56 NK and CD3 T cells and CD45 viable tumor cells from STS patients undergoing surgery. We then evaluated differential gene expression (DGE) of these purified populations with RNA sequencing analysis. To evaluate survival differences and validate primary DGE results, we also queried The Cancer Genome Atlas (TCGA) database to compare outcomes stratified by bulk gene expression.
Sorted intra-tumoral CD3 T cells showed significant upregulation of established activating (CD137) and inhibitory genes (TIM-3) compared to circulating T cells. In contrast, intra-tumoral NK cells did not exhibit upregulation of canonical cytotoxic genes (IFNG, GZMB), but rather significant DGE in mitogen signaling (DUSP4) and metabolic function (SMPD3, SLC7A5). Tumors with higher NK and T cell infiltration exhibited significantly increased expression of the pro-inflammatory receptor TLR4 in sorted CD45 tumor cells. TCGA analysis revealed that tumors with high TLR4 expression ( = 0.03) and low expression of STMN1 involved in microtubule polymerization ( < 0.001) were associated with significantly improved survival.
Unlike T cells, which demonstrate significant DGE consistent with upregulation of both activating and inhibiting receptors in tumor-infiltrating subsets, NK cells appear to have more stable gene expression between blood and tumor subsets, with alterations restricted primarily to metabolic pathways. Increased immune cell infiltration and improved survival were positively correlated with TLR4 expression and inversely correlated with STMN1 expression within tumors, suggesting possible novel therapeutic targets for immunotherapy in STS.
目前基于 T 细胞的免疫疗法在软组织肉瘤(STS)中的临床疗效有限,而临床前研究已经表明自然杀伤(NK)细胞活性的证据。由于肿瘤免疫浸润,尤其是肿瘤浸润淋巴细胞,与大多数实体瘤的生存改善相关,我们试图评估肿瘤和血液 NK 和 T 细胞以及肿瘤细胞的基因表达谱,以确定 STS 中潜在的新免疫靶标。
使用荧光激活细胞分选,我们从接受手术的 STS 患者中分离血液和肿瘤浸润性 CD3CD56NK 和 CD3T 细胞和 CD45 活肿瘤细胞。然后,我们使用 RNA 测序分析评估这些纯化群体的差异基因表达(DGE)。为了评估生存差异并验证主要 DGE 结果,我们还查询了癌症基因组图谱(TCGA)数据库,以按批量基因表达分层比较结果。
与循环 T 细胞相比,分选的肿瘤内 CD3T 细胞显示出已建立的激活(CD137)和抑制基因(TIM-3)的显着上调。相比之下,肿瘤内 NK 细胞没有表现出经典细胞毒性基因(IFNG,GZMB)的上调,而是在有丝分裂信号(DUSP4)和代谢功能(SMPD3,SLC7A5)中表现出显着的 DGE。具有更高 NK 和 T 细胞浸润的肿瘤在分选的 CD45 肿瘤细胞中表现出促炎受体 TLR4 的表达显着增加。TCGA 分析显示,高 TLR4 表达( = 0.03)和参与微管聚合的 STMN1 低表达(<0.001)的肿瘤与生存率显着提高相关。
与 T 细胞不同,T 细胞在肿瘤浸润亚群中表现出明显的 DGE,一致上调激活和抑制受体,而 NK 细胞在血液和肿瘤亚群之间的基因表达似乎更稳定,改变主要局限于代谢途径。肿瘤内免疫细胞浸润增加和生存率提高与 TLR4 表达呈正相关,与肿瘤内 STMN1 表达呈负相关,这表明 STS 免疫治疗的潜在新治疗靶点。